Search Results - "Wildiers, J."

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over by PARIDAENS, R, BIGANZOLI, L, AWADA, A, WILDIERS, J, PICCART, M, BRUNING, P, KLIJN, J. G. M, GAMUCCI, T, HOUSTON, S, COLEMAN, R, SCHACHTER, J, VAN VRECKEM, A, SYLVESTER, R

“…To compare the efficacy of paclitaxel versus doxorubicin given as single agents in first-line therapy of advanced breast cancer (primary end point,…”
Get full text

The requirements of a specialist breast unit by EUSOMA

Get full text

Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy by Fentiman, I.S, Christiaens, M.-R, Paridaens, R, Van Geel, A, Rutgers, E, Berner, J, de Keizer, G, Wildiers, J, Nagadowska, M, Legrand, C, Therasse, P

“…For treatment of early breast cancer in older women, little evidence is available from randomised trials. We conducted a randomised trial comparing modified…”
Get full text

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group by Clavel, M, Vermorken, J B, Cognetti, F, Cappelaere, P, de Mulder, P H, Schornagel, J H, Tueni, E A, Verweij, J, Wildiers, J, Clerico, M

“…The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus…”
Get more information

Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists’ preferences by Nooij, M.A, de Haes, J.C.J.M, Beex, L.V.A.M, Wildiers, J, Klijn, J, Becquart, D, Jassem, J, Engelsman, E, Duchateau, L

“…The optimal duration of cytostatic treatment for metastatic breast cancer is still a matter of debate. Possible gain in the duration of remission has to be…”
Get full text

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion by VINHOLES, J, COLEMAN, R, MIGNOLET, F, FORD, J, LACOMBE, D, ROSE, C, TUBIANA-HULIN, M, BASTIT, P, WILDIERS, J, MICHEL, J, LEONARD, R, NORTIER, J

“…This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs for the assessment of response…”
Get full text

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer by Paridaens, R., Van Aelst, F., Georgoulias, V., Samonnig, H., Cocquyt, V., Zielinski, C., Hausmaninger, H., Willemse, P., Boudraa, Y., Wildiers, J., Ramazeilles, C., Azli, N.

“…Background: This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line…”
Get full text

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer by BONTENBAL, M, ANDERSSON, M, VAN OOSTEROM, A. T, WILDIERS, J, COCCONI, G, JASSEM, J, PARIDAENS, R, ROTMENSZ, N, SYLVESTER, R, MOURIDSEN, H. T, KLIJN, J. G. M

Get full text

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study by Schornagel, J H, Verweij, J, de Mulder, P H, Cognetti, F, Vermorken, J B, Cappelaere, P, Armand, J P, Wildiers, J, de Graeff, A, Clavel, M

“…To compared the response rates and the toxicity of the new antifolate edatrexate (EDX) with that of methotrexate (MTX) in a randomized trial in patients with…”
Get more information

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck by Verweij, J., de Mulder, P. H. M, de Graeff, A., Vermorken, J. B., Wildier, J., Kerger, J., Schornagel, J., Cognetti, F., Kirkpatrick, A., Sahmoud, T., Lefebvre, J. L.

“…Background: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. Patients and methods: Patients with…”
Get full text

Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study by Paridaens, R, Thomas, J, Wildiers, J, Vermeiren, P, Lobelle, J P, di Salle, E, Ornati, G, Zurlo, M G, Polli, A, Lanzalone, S, de Belder, K

“…Exemestane is an irreversible, steroidal, oral aromatase inhibitor under evaluation in postmenopausal women with advanced breast cancer. A phase I study was…”
Get more information

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer by Piccart, M J, Bruning, P, Wildiers, J, Awada, A, Schornagel, J H, Thomas, J, Tomiak, E, Bartholomeus, S, Witteveen, P O, Paridaens, R

“…In an attempt to increase chemotherapy dose intensity by step-wise reduction of the time interval between treatment cycles, filgrastim was administered to…”
Get more information

Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer by Lemmens, J., Berteloot, P., Thomas, J., Wildiers, J., Paridaens, R.

Get full text

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group by Bontenbal, M, Andersson, M, Wildiers, J, Cocconi, G, Jassem, J, Paridaens, R, Rotmensz, N, Sylvester, R, Mouridsen, H T, Klijn, J G, van Oosterom, A T

“…The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with…”
Get full text

Docetaxel is A Potent Cytotoxic Drug in the Treatment of Advanced Breast Cancer by Vaerenbergh W, Van, Paridaens, R., Thomas, J., Wildiers, J., Van Oosterom, A.

“…Docetaxel (Taxotere®) belongs to a new class of anti-neoplastic agents, the taxanes. As the structurally related compound, paclitaxel, it enhances microtubule…”
Get full text

Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study by Klijn, Jan G. M., Beex, Louk V. A. M., Mauriac, Louis, van Zijl, Jacobus A., Veyret, Corinne, Wildiers, Johan, Jassem, Jacek, Piccart, Martine, Burghouts, Jos, Becquart, Dominique, Seynaeve, Carolien, Mignolet, Françoise, Duchateau, Luc

“…Background: Surgical or medical castration and antiestrogenic treatment with tamoxifen are common endocrine treatments for premenopausal women with breast…”
Get full text

Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck by Clavel, M, Cognetti, F, Dodion, P, Wildiers, J, Rosso, R, Rossi, A, Gignoux, B, Van Rymenant, M, Cortes-Funes, H, Dalesio, O

“…A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin,…”
Get more information

Acute blindness during treatment of recurrent or metastatic nasopharyngeal carcinoma with doxorubicin and CCNU by Schornagel, J H, Verweij, J, de Mulder, P H, Wildiers, J, Kirkpatrick, A, Cognetti, F

Get more information

Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861) by Bruning, P F, Bonfrèr, J M, Wildiers, J, Jassem, J, Beex, L V, Schornagel, J, Nooijen, W J

“…The supposed mechanism of action of aminoglutethimide (AG), medical adrenalectomy, has been challenged. AG is now considered to act as an inhibitor of the…”
Get more information

Relevance of hydroxyproline excretion to bone metastasis in breast cancer by Gielen, F, Dequeker, J, Drochmans, A, Wildiers, J, Merlevede, M

“…In 181 consecutive patients with breast cancer, urinary hydroxyproline excretion has been critically evaluated in conjunction with clinical, biochemical,…”
Get full text